Paul Hudson
"I was raised in a family that respected the value that you 'treat other people like you would like to be treated yourself.' I've always tried to live by that. Some days are harder than others. That's a sort of a compass bearing for me."
— Paul Hudson[1]
Overview
Paul Hudson | |
|---|---|
 | |
| Born | October 14, 1967 Manchester, England |
| Citizenship | British |
| Education | Degree in economics |
| Alma mater | Manchester Metropolitan University |
| Occupation(s) | Pharmaceutical executive; Chief executive officer |
| Employer | Sanofi |
| Known for | Restructuring Sanofi and emphasising AI-enabled, R&D-led growth |
| Title | Chief executive officer |
| Term | September 2019 – present |
| Predecessor | Olivier Brandicourt |
| Board member of | Board chair-elect (2026), PhRMA |
| Spouse | Sandra Hudson |
| Children | 3 |
| Awards | Honorary Doctor of Business Administration, Manchester Metropolitan University (2018) |
| Website | https://www.sanofi.com/en/our-company/governance/executive-committee/paul-hudson |
👤 Paul Hudson (born 14 October 1967) is a British pharmaceutical executive who has served as chief executive officer (CEO) of Sanofi since September 2019.[5][6] He previously led Novartis Pharmaceuticals and held senior roles at AstraZeneca, having begun his career in sales and marketing at GlaxoSmithKline and Sanofi’s UK predecessor business.[7][8] Under his leadership Sanofi has pursued a strategy of concentrating on specialty medicines and vaccines, coupled with what company communications describe as an R&D-driven, AI-enabled approach to growth, while remaining one of the world’s major pharmaceutical groups by revenue.[8][9]
🧭 Strategic repositioning at Sanofi. Since taking charge of Sanofi in 2019, Hudson has overseen a sweeping strategic refocus that shifted research resources away from diabetes and cardiovascular disease towards oncology, immunology and vaccines; restructured the business into three core divisions; and carved out the consumer healthcare arm, Opella, with a view to unlocking value through partnerships or a partial separation.[10][11] The reorientation has been accompanied by significant investment in digital technologies and partnerships, particularly in artificial intelligence (AI), and by an expansion of high-growth products such as the immunology drug Dupixent and the infant RSV antibody Beyfortus.[11][7][9]
Early life and education
🎓 Manchester upbringing and studies. Hudson was born in Manchester, England, on 14 October 1967, to a working-class family; his father worked as an accountant and his mother designed window displays for fashion boutiques.[7] He has described being raised with a strong moral compass and guided by the maxim to “treat other people as you would like to be treated yourself”, which he cites as a lifelong compass.[7][12] He studied economics at Manchester Metropolitan University (then Manchester Polytechnic), graduating in 1990, and in 2018 the university awarded him an honorary Doctor of Business Administration in recognition of his achievements in the pharmaceutical industry.[7][6]
💊 Entry into pharmaceuticals. Rather than following classmates into banking, consulting or retail, Hudson decided to work in healthcare after a conversation with a doctor in his extended family, who suggested he might enjoy “being in and around health”; he later recalled that the idea “struck a nerve” and shaped his career choice.[11] Eschewing fast-track graduate schemes, he began in the early 1990s as a sales and marketing representative at GlaxoSmithKline and at Sanofi-Synthélabo’s UK affiliate, spending around five years carrying a sales bag and developing a detailed understanding of medicines and patient needs before moving into management roles.[7][12]
Career
🌏 AstraZeneca in Japan and North America. Hudson’s progression into senior management accelerated at AstraZeneca, where he held a series of posts across Europe and North America before being appointed president of the company’s Japanese business in 2011.[7][5] He arrived in Japan just days before the Tōhoku earthquake, tsunami and Fukushima nuclear disaster, and later recalled calling his supervisor for guidance and being told that there was no precedent and that he would have to rely on his own judgement—an experience he has described as formative in crisis leadership.[7] In 2013 he became president of AstraZeneca’s North America division and executive vice-president for North America, taking responsibility for the company’s U.S. operations.[5]
💼 Novartis Pharmaceuticals leadership. In 2016 Hudson joined Swiss group Novartis as chief executive of its Pharmaceuticals division, overseeing a global portfolio of patented medicines and helping steer a reorganisation that separated Novartis Pharmaceuticals and Novartis Oncology into distinct business units.[5][8] The role broadened his exposure to specialty drugs and biologics, and positioned him as a candidate for top-level leadership in the global pharmaceutical industry.
🏢 Appointment as Sanofi chief executive. In June 2019 Sanofi announced that its board had unanimously selected Hudson to succeed Olivier Brandicourt as chief executive officer, with effect from September that year.[5][6] He became one of the first non-French nationals to lead the company, taking charge of a business with around 100,000 employees and a sizeable presence in vaccines, general medicines and consumer healthcare, but whose research pipeline and diabetes franchise had been under pressure.[7][10]
Leadership at Sanofi
🔁 Strategic refocus and portfolio simplification. Within his first months at Sanofi, Hudson unveiled a strategic plan that ended in-house research into diabetes and cardiovascular diseases, areas in which the company had long been a leading insulin supplier but where its prospects for breakthrough innovation were seen as limited.[10] Announced in December 2019, the plan aimed to redirect resources toward oncology, immunology, rare diseases and vaccines, while targeting €2 billion in cost savings and a core operating margin of around 30% by 2022.[10] As part of the same shift, Sanofi agreed to acquire U.S. biotech Synthorx for about $2.5 billion to bolster its immuno-oncology pipeline and reorganised its structure from five business units into three—Specialty Care, Vaccines and General Medicines—alongside a more autonomous consumer healthcare division branded Opella.[10][7][11] By 2023 Sanofi had sold a 50% stake in Opella to private-equity group Clayton, Dubilier & Rice, reinforcing its focus on prescription medicines and vaccines.[11]
🤖 Digital transformation and AI initiatives. Hudson made digitalisation and data science a central theme of his tenure, creating Sanofi’s first chief digital officer position and launching partnerships with technology companies such as Google to apply advanced analytics and AI to drug development, clinical trials and supply-chain management.[7][12] Early projects ranged from attempting to use algorithms to optimise insulin dosing for people with diabetes to large-scale analysis of de-identified healthcare datasets under the “Darwin” programme.[7] Hudson has argued that the pharmaceutical sector has lagged other industries in exploiting digital tools and has championed an “end-to-end” AI strategy across Sanofi’s value chain, presenting the company as an R&D-driven, AI-enabled biopharma business.[12][8]
🧪 Product pipeline and key medicines. A central element of Hudson’s strategy has been to concentrate on a smaller number of high-growth medicines. He backed the interleukin-4/13 monoclonal antibody Dupixent early in his tenure, forecasting that it could achieve annual sales above €10 billion, and oversaw its expansion from atopic dermatitis into asthma, chronic rhinosinusitis with nasal polyps and other inflammatory diseases.[10][11] Under Hudson, Sanofi has also pursued new treatments in neurology and immunology, including a multiple sclerosis drug that delayed progression of a progressive form of the disease in late-stage trials, and has strengthened its vaccines and antibody portfolio through products such as Beyfortus, an RSV monoclonal antibody developed with AstraZeneca that reduced hospitalisations among infants in Spain by about 82% in its first season of use.[11]
📈 Market reception and shareholder returns. Hudson’s strategy, which has favoured increased research and development spending over near-term profit targets, initially unsettled investors: when Sanofi abandoned its medium-term operating-margin goals in 2023 to finance additional R&D, the company’s share price fell by about 19%.[11] As new products such as Dupixent and Beyfortus delivered strong growth, the stock recovered; by early September 2024 Sanofi’s shares had reached an all-time closing high of €105.76, and the group ranked among the largest constituents of France’s CAC 40 index by market capitalisation.[11] Over the three years to 2025, Sanofi’s earnings per share declined by around 3.3% annually, while total shareholder return was approximately 1.1%, leading some commentators to characterise Hudson’s record as one of modest but improving performance after a period of stagnation.[13]
💶 CEO remuneration. As chief executive of a company valued at more than €100 billion, Hudson receives a pay package that is substantial by European standards but lower than that of many U.S. pharmaceutical chiefs. In 2023 his total compensation amounted to €10.57 million, including a fixed salary of €1.4 million and variable elements such as performance-related bonuses and equity awards.[14] This represented a slight decline from his first full year at Sanofi in 2020, when sign-on incentives related to his move from Novartis boosted his pay to about €11.3 million.[14] Comparative analyses have placed his remuneration close to the median for European “big pharma” CEOs and considerably below the highest-paid U.S. peers, such as AstraZeneca’s Pascal Soriot.[14][13]
📊 Wealth and equity stake. Beyond annual pay, Hudson holds a personal stake in Sanofi through share ownership and long-term incentive plans. As of 2025 he was estimated to control Sanofi shares worth around €12 million, or roughly 0.01% of the company, aligning his financial interests with those of other shareholders without placing him in the class of billionaire founder-owners seen at some healthcare companies.[13][6]
Industry roles and public engagement
🏛️ Industry association leadership. In addition to his responsibilities at Sanofi, Hudson holds positions in broader industry governance. He serves on the board of the PhRMA trade association and has been elected as its board chair for 2026, succeeding Pfizer CEO Albert Bourla.[8] In this role he is expected to be a prominent voice in debates on drug pricing, intellectual-property protection and healthcare reform in the United States, complementing his advocacy on industrial policy and innovation in Europe.[8][11]
📣 Policy positions and advocacy. Hudson has been outspoken on issues such as access to medicines and the competitiveness of European and British life sciences. In the UK he has criticised what he sees as short-sighted rationing of new treatments by the National Health Service (NHS), arguing that slow reimbursement decisions deter clinical trials and investment, and he has warned that the country is “at the back of the race of turtles” in life sciences unless policies change.[11] He has urged governments in Europe to increase support for biotechnology, expand health-data infrastructure and streamline regulation, contending that otherwise the region risks falling behind the United States and China in innovation.[11][7]
🌱 Environmental, social and governance priorities. Under Hudson’s leadership Sanofi has strengthened its environmental and social commitments, including targets to achieve carbon neutrality across its operations by 2030 and net-zero greenhouse-gas emissions across its value chain by 2045.[12][15] The company has joined initiatives such as the RE100 renewable-electricity coalition and reports that all of its French sites already use renewable power on the way to a global 2030 target.[15][16] Hudson frequently links these commitments to Sanofi’s purpose of “chasing the miracles of science to improve people’s lives” and has framed ESG as integral to the company’s business performance rather than separate from it.[8][6]
Personal life and leadership style
🏠 Family and relocation to France. Hudson is married to his wife Sandra, with whom he has three children, and has spoken about how his family helps him maintain perspective and test his ideas about social and technological change.[7][11][6] After taking the helm at Sanofi he relocated from London to Paris, where he embraced everyday aspects of French life, joking that his command of the language is “flawless in restaurants” even if not in boardrooms and becoming known for commuting around the city on an electric scooter (trottinette).[11]
⚽ Football influences and management philosophy. A lifelong supporter of Manchester United, Hudson has kept a season ticket at Old Trafford and often uses football metaphors to describe research and development, urging colleagues to take “more shots on goal” and to prioritise teamwork over individual stardom.[7][11] He has cited the club’s former manager Sir Alex Ferguson as a leadership role model, admiring Ferguson’s insistence that everyone from cleaners to star players be treated with respect and that the team should always come before any one individual.[7] Hudson has said he tries to foster a similar ethos at Sanofi, stressing that no executive is more important than the company’s mission or its patients.
😊 Personality and workplace culture. Colleagues and interviewers have described Hudson’s leadership style as direct, energetic and informal, with an emphasis on approachability and open dialogue.[7][12] He has popularised maxims such as “take your work seriously, but don’t take yourself too seriously” and has highlighted advice from a former boss to “stay grounded, stay humble, know what you know, know what you don’t know, be willing to talk about it” as guiding principles in senior roles.[12][17] Hudson has said that his relaxation “often revolves around three things: family, food and football”, and he credits these anchors with helping him navigate the pressures of running a global pharmaceutical company.[11]
Controversies and challenges
⚠️ COVID-19 vaccine priority dispute. One of the earliest controversies of Hudson’s tenure arose in May 2020, when a Bloomberg interview was reported as suggesting that if Sanofi developed a COVID-19 vaccine, the United States—having provided substantial early funding through its BARDA agency—would receive first access.[7][11] The remark provoked strong criticism in France, where politicians and media questioned why a French-headquartered company benefiting from national tax incentives might prioritise another country, and Hudson faced a surge of public and internal backlash.[7] He subsequently wrote to employees to apologise for the “uncomfortable situation” created by the misunderstanding, emphasised that Sanofi aimed to supply any successful vaccine to Europe and the United States at the same time, and argued that the episode underlined the need for a “Europe that prioritises healthcare” and greater investment in vaccine manufacturing capacity.[7]
🦠 COVID-19 vaccine race and R&D setbacks. Despite its long history in vaccines, Sanofi did not ultimately bring a COVID-19 vaccine to market at scale, after delays to its candidate developed with GSK and the decision to discontinue a dedicated mRNA COVID programme.[11][7] The episode prompted criticism of the company’s research agility and highlighted the difficulty of competing with faster-moving rivals such as Pfizer, Moderna and AstraZeneca in pandemic conditions. Hudson has acknowledged the disappointment but has pointed to Sanofi’s contribution to global vaccine supply through manufacturing support for other producers and to the redeployment of resources towards areas such as RSV antibodies and next-generation influenza vaccines.[11][12]
🧮 Balancing investment and short-term performance. Hudson’s decision to remove Sanofi’s medium-term margin targets and increase R&D expenditure has remained a focus of investor debate. Some shareholders and analysts criticised the move as weakening financial discipline at a time when the company’s earnings per share were declining, while others argued that rebuilding the pipeline required sacrificing short-term profitability.[11][13] Sanofi’s revenues grew by more than 7% in 2022 and have accelerated further as Dupixent, Beyfortus and other newer medicines expanded, yet the company’s three-year total shareholder return to 2025 remained broadly flat, reinforcing the view that Hudson must still demonstrate sustained value creation alongside scientific progress.[13][9]
Legacy and assessment
📚 Overall legacy and ongoing impact. Commentators have portrayed Hudson’s trajectory from a Manchester sales representative to the leadership of Sanofi as characteristic of a career corporate executive who combines ground-level experience with global strategic responsibilities.[7][8] Under his stewardship the company has exited some long-standing but low-growth franchises, invested heavily in biologics, immunology and AI-enabled R&D, and sought to position itself as a major player in vaccines and specialty medicines.[10][11][9] Hudson himself has said that “people are what drive me” and that he was drawn to healthcare to have a positive impact on patients’ lives, an ethos that continues to inform his public messaging and internal priorities as he leads Sanofi through what he and others describe as a period of rapid scientific and technological change.[6][8][12]
Related content & more
YouTube videos
biz/articles
References
- ↑ "Stay grounded, stay humble: Sanofi CEO Paul Hudson". McKinsey & Company.
- ↑ "Stay grounded, stay humble: Sanofi CEO Paul Hudson". McKinsey & Company.
- ↑ "Paul Hudson: A Mindset for Miracles". Pharmaceutical Executive.
- ↑ "Paul Hudson: A Mindset for Miracles". Pharmaceutical Executive.
- ↑ 5.0 5.1 5.2 5.3 5.4 "Paul Hudson (businessman)". Wikipedia. Retrieved 2025-11-20.
- ↑ 6.0 6.1 6.2 6.3 6.4 6.5 6.6 "Paul Hudson". Sanofi. Retrieved 2025-11-20.
- ↑ 7.00 7.01 7.02 7.03 7.04 7.05 7.06 7.07 7.08 7.09 7.10 7.11 7.12 7.13 7.14 7.15 7.16 7.17 7.18 7.19 7.20 7.21 "Paul Hudson: A vaccine for everyone!". HEC Stories. 29 June 2020. Retrieved 2025-11-20.
- ↑ 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 "Paul Hudson: A Mindset for Miracles". Pharmaceutical Executive. 17 September 2025. Retrieved 2025-11-20.
- ↑ 9.0 9.1 9.2 9.3 "Q4 2024 sales growth of 10.3%, 2024 business EPS guidance exceeded" (PDF). Sanofi. 30 January 2025. Retrieved 2025-11-20.
- ↑ 10.0 10.1 10.2 10.3 10.4 10.5 10.6 "Sanofi ends research in diabetes, narrows units to spur profit". Reuters. 9 December 2019. Retrieved 2025-11-20.
- ↑ 11.00 11.01 11.02 11.03 11.04 11.05 11.06 11.07 11.08 11.09 11.10 11.11 11.12 11.13 11.14 11.15 11.16 11.17 11.18 11.19 11.20 "'The UK is at the back of the race of turtles': Sanofi's boss on the need to develop new medicines". The Guardian. 15 October 2024. Retrieved 2025-11-20.
- ↑ 12.0 12.1 12.2 12.3 12.4 12.5 12.6 12.7 12.8 "'Stay grounded, stay humble': Sanofi CEO Paul Hudson". McKinsey Health Institute. 11 January 2023. Retrieved 2025-11-20.
- ↑ 13.0 13.1 13.2 13.3 13.4 "We think Sanofi's (EPA:SAN) CEO May Struggle To See Much Of A Pay Rise This Year". Simply Wall St. 23 April 2025. Retrieved 2025-11-20.
- ↑ 14.0 14.1 14.2 "Sanofi CEO Paul Hudson takes another small dip in pay to €10.57M". FiercePharma. 26 February 2024. Retrieved 2025-11-20.
- ↑ 15.0 15.1 "The future for energy: consuming less, smarter and more sustainably". Sanofi. 7 June 2023. Retrieved 2025-11-20.
- ↑ "ESG Index: Climate". Sanofi. Retrieved 2025-11-20.
- ↑ "Quote of the day: Paul Hudson". McKinsey & Company. 13 January 2023. Retrieved 2025-11-20.